NovoCure Ltd (NASDAQ: NVCR) kicked off on Monday, down -5.46% from the previous trading day, before settling in for the closing price of $17.21. Over the past 52 weeks, NVCR has traded in a range of $10.87-$24.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 17.16% over the last five years. While this was happening, its average annual earnings per share was recorded 29.81%. With a float of $97.51 million, this company’s outstanding shares have now reached $107.08 million.
The firm has a total of 1453 workers. Let’s measure their productivity. In terms of profitability, gross margin is 75.82%, operating margin of -33.65%, and the pretax margin is -25.66%.
NovoCure Ltd (NVCR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 9.89%, while institutional ownership is 85.76%. The most recent insider transaction that took place on Aug 02 ’24, was worth 13,857. In this transaction Chief Financial Officer of this company sold 688 shares at a rate of $20.14, taking the stock ownership to the 219,179 shares. Before that another transaction happened on Jun 04 ’24, when Company’s Director sold 964 for $23.89, making the entire transaction worth $23,033. This insider now owns 164,833 shares in total.
NovoCure Ltd (NVCR) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.46 earnings per share (EPS), higher than consensus estimate (set at -0.52) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.81% per share during the next fiscal year.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Take a look at NovoCure Ltd’s (NVCR) current performance indicators. Last quarter, stock had a quick ratio of 6.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Analysing the last 5-days average volume posted by the [NovoCure Ltd, NVCR], we can find that recorded value of 2.79 million was better than the volume posted last year of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 33.79%. Additionally, its Average True Range was 1.27.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 20.53%, which indicates a significant decrease from 27.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.59% in the past 14 days, which was higher than the 65.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.00, while its 200-day Moving Average is $16.80. Now, the first resistance to watch is $16.94. This is followed by the second major resistance level at $17.61. The third major resistance level sits at $18.15. If the price goes on to break the first support level at $15.73, it is likely to go to the next support level at $15.19. Should the price break the second support level, the third support level stands at $14.52.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
The company with the Market Capitalisation of 1.76 billion has total of 107,611K Shares Outstanding. Its annual sales at the moment are 509,340 K in contrast with the sum of -207,040 K annual income. Company’s last quarter sales were recorded 150,360 K and last quarter income was -33,380 K.
